Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026
Autonomix Medical, Inc. announced that their long-term data on mitigating pain from pancreatic adenocarcinoma using transvascular RF energy-based ablation has been accepted for presentation at Digestive Disease Week 2026 in Chicago. The findings highlight the potential of their innovative treatment approach to significantly improve patient quality of life by disrupting nerve signaling responsible for pain. The presentation will take place during one of the world’s leading conferences for advancements in gastroenterology and related fields.
THE WOODLANDS, TX, April 29, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its long-term data titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation” has been accepted for presentation at Digestive Disease Week 2026 (DDW 2026), being held May 2–5, 2026, in Chicago, IL and virtually.